Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Treatment of multiple myeloma.

Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J.

Blood. 2004 Jan 1;103(1):20-32. Epub 2003 Sep 11. Review.

2.

Treatment of myeloma: recent developments.

Zweegman S, Huijgens PC.

Anticancer Drugs. 2002 Apr;13(4):339-51. Review.

PMID:
11984079
3.

Triple transplantation of autologous peripheral blood stem cells each time following conditioning with 100 mg/m2 of melphalan for multiple myeloma patients in poor performance status.

Rokicka M, Urbanowska E, Torosian T, Dwilewicz-Trojaczek J, Awedan A, Paluszewska M, Wiktor-Jedrzejczak W.

Transplant Proc. 2003 Sep;35(6):2352-4.

PMID:
14529939
4.

Advances in biology and therapy of multiple myeloma.

Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G.

Hematology Am Soc Hematol Educ Program. 2003:248-78. Review.

PMID:
14633785
5.

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR.

Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708.

6.

Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.

Inamoto Y, Kurahashi S, Imahashi N, Fukushima N, Adachi T, Kinoshita T, Tsushita K, Miyamura K, Naoe T, Sugiura I.

Am J Hematol. 2009 May;84(5):283-6. doi: 10.1002/ajh.21390.

7.

Treatment of myeloma in patients not eligible for transplantation.

Jagannath S.

Curr Treat Options Oncol. 2005 May;6(3):241-53. Review.

PMID:
15869735
8.

Breakthroughs in the management of multiple myeloma.

Heffner LT Jr, Lonial S.

Drugs. 2003;63(16):1621-36. Review.

PMID:
12904084
9.

Treatment of multiple myeloma: an emphasis on new developments.

Kyle RA, Vincent Rajkumar S.

Ann Med. 2006;38(2):111-5. Review.

PMID:
16581696
10.

[Intensive treatment of multiple myeloma].

Harousseau JL.

Bull Acad Natl Med. 2003;187(2):405-13; discussion 413-5. Review. French.

PMID:
14556449
11.

[Treatment of multiple myeloma--melphalan monotherapy after bone marrow transplantation].

Hájek R, Adam Z, Krejcí M, Vásová I, Král Z, Vorlícek J.

Vnitr Lek. 1996 Apr;42(4):278-84. Review. Czech.

PMID:
8693716
12.

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.

Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N.

J Clin Oncol. 2009 Apr 10;27(11):1788-93. doi: 10.1200/JCO.2008.18.8573. Epub 2009 Mar 9.

PMID:
19273705
13.

Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.

Barlogie B.

Semin Hematol. 2003 Oct;40(4 Suppl 4):33-8. Review.

PMID:
15015894
14.

Current therapy of multiple myeloma.

Kyle RA.

Intern Med. 2002 Mar;41(3):175-80. Review.

15.

MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.

Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A, Zangari M, Giroux D, Crowley J, Hough A, Sawyer J.

Br J Haematol. 2003 Aug;122(3):430-40.

PMID:
12877670
16.

Melphalan and its role in the management of patients with multiple myeloma.

Falco P, Bringhen S, Avonto I, Gay F, Morabito F, Boccadoro M, Palumbo A.

Expert Rev Anticancer Ther. 2007 Jul;7(7):945-57. Review.

PMID:
17627453
17.

The role of immunomodulatory drugs in multiple myeloma.

Anderson KC.

Semin Hematol. 2003 Oct;40(4 Suppl 4):23-32. Review.

PMID:
15015893
18.

Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis.

Hillengass J, Ho AD, Goldschmidt H, Waldherr R, Moehler TM.

Int J Hematol. 2008 Nov;88(4):454-6. doi: 10.1007/s12185-008-0177-1. Epub 2008 Oct 11.

PMID:
18846323
20.

Advances in therapy of multiple myeloma.

Bladé J, Rosiñol L.

Curr Opin Oncol. 2008 Nov;20(6):697-704. doi: 10.1097/CCO.0b013e3283136984. Review.

PMID:
18841053

Supplemental Content

Support Center